Intervacc AB
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages… Read more
Market Cap & Net Worth: Intervacc AB (IVACC)
Intervacc AB (ST:IVACC) has a market capitalization of $22.48 Million (Skr252.20 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27300 globally and #368 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intervacc AB's stock price Skr0.74 by its total outstanding shares 340813188 (340.81 Million).
Intervacc AB Market Cap History: 2017 to 2026
Intervacc AB's market capitalization history from 2017 to 2026. Data shows change from $230.89 Million to $22.48 Million (-23.03% CAGR).
Index Memberships
Intervacc AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$4.63 Billion | 0.29% | #76 of 281 |
Weight: Intervacc AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Intervacc AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intervacc AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.02x
Intervacc AB's market cap is 3.02 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $230.89 Million | $48.00 Million | -$12.77 Million | 4.81x | N/A |
| 2018 | $203.55 Million | $35.60 Million | -$27.49 Million | 5.72x | N/A |
| 2019 | $548.37 Million | $12.14 Million | -$27.89 Million | 45.17x | N/A |
| 2020 | $1.60 Billion | $4.78 Million | -$25.60 Million | 335.58x | N/A |
| 2021 | $1.62 Billion | $5.24 Million | -$29.38 Million | 308.38x | N/A |
| 2022 | $789.89 Million | $9.68 Million | -$64.16 Million | 81.57x | N/A |
| 2023 | $192.31 Million | $8.02 Million | -$102.85 Million | 23.99x | N/A |
| 2024 | $35.55 Million | $11.79 Million | -$75.52 Million | 3.02x | N/A |
Competitor Companies of IVACC by Market Capitalization
Companies near Intervacc AB in the global market cap rankings as of March 19, 2026.
Key companies related to Intervacc AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Intervacc AB Historical Marketcap From 2017 to 2026
Between 2017 and today, Intervacc AB's market cap moved from $230.89 Million to $ 22.48 Million, with a yearly change of -23.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr22.48 Million | -19.91% |
| 2025 | Skr28.07 Million | -21.03% |
| 2024 | Skr35.55 Million | -81.52% |
| 2023 | Skr192.31 Million | -75.65% |
| 2022 | Skr789.89 Million | -51.13% |
| 2021 | Skr1.62 Billion | +0.76% |
| 2020 | Skr1.60 Billion | +192.52% |
| 2019 | Skr548.37 Million | +169.40% |
| 2018 | Skr203.55 Million | -11.84% |
| 2017 | Skr230.89 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Intervacc AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.48 Million USD |
| MoneyControl | $22.48 Million USD |
| MarketWatch | $22.48 Million USD |
| marketcap.company | $22.48 Million USD |
| Reuters | $22.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.